Biogen Tender Offer for Apellis Pharmaceuticals Successfully Completed; Merger Imminent

summarizeSummary

Biogen has successfully completed its tender offer for Apellis Pharmaceuticals, with 82.4% of shares tendered, and expects to finalize the merger today, resulting in Apellis's delisting.

check_boxKey Events

• Tender Offer Completed

  Biogen's tender offer for Apellis Pharmaceuticals expired on May 13, 2026, with 82.4% of outstanding shares validly tendered and accepted for payment.

• Merger Consummation

  All conditions for the merger have been satisfied or waived, and the acquisition is expected to be consummated today, May 14, 2026, making Apellis a wholly-owned subsidiary of Biogen.

• Delisting and Deregistration

  Apellis shares will be delisted from the Nasdaq Global Select Market, and the company will cease its SEC reporting obligations.

auto_awesomeAnalysis

This filing confirms the successful completion of Biogen's tender offer for Apellis Pharmaceuticals. With 82.4% of shares tendered, all conditions have been met, and the merger is expected to close today, May 14, 2026. This marks the final step in Apellis becoming a wholly-owned subsidiary of Biogen, leading to its delisting from Nasdaq and the cessation of its public reporting obligations.